F

Fresno Clinical Research Center | Fresno, CA

Research site

(Unclaimed)

Location

7055 N Maple Avenue, Suite 106, Fresno, California, United States of America

Site insights

Top conditions

Top treatments

Selonsertib

MGL-3196

LY3298176

Cenicriviroc

Relamorelin

EDP-305

HTD1801

Obeticholic Acid

Cilofexor

Elafibranor

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 16 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling

Non-Alcoholic Fatty Liver Disease

Drug: Resmetirom

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

Procedure: Liver Biopsy

Drug: MGL-3196

A Study of BOS-580 in Obese Subjects At Risk For, or with Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) with an Extension

This is a randomized, blinded, placebo-controlled study of BOS-580 in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohe...

Enrolling

Nonalcoholic Steatohepatitis (NASH)

Drug: Placebo

Drug: BOS-580